Failure Narrows Odds On Targacept Depression Drug; Hope Rests In Remaining Three Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Nicotinic receptor company Targacept and TC-5214 partner AstraZeneca remain committed to a 2H 2012 filing of the drug as adjunct therapy for major depressive disorder.
You may also be interested in...
Targacept, AstraZeneca Face Another Failure With NNR Class
The Targacept/AstraZeneca partnership faces another major setback as they decide not to file their neuronal nicotinic receptor modulator TC-5214 in major depressive disorder. Targacept CEO chalks the trial failure up to the gray areas of depression trial design.
Targacept, AstraZeneca Face Another Failure With NNR Class
The Targacept/AstraZeneca partnership faces another major setback as they decide not to file their neuronal nicotinic receptor modulator TC-5214 in major depressive disorder. Targacept CEO chalks the trial failure up to the gray areas of depression trial design.
AstraZeneca Takes Impairment Charge After Olaparib, TC-5214 Setbacks
Olaparib and TC-5214 development setbacks at AstraZeneca lead to $380 million charge in the fourth quarter, with core EPS likely at the bottom of the expected range.